ImuMed International To Acquire Symbolistics Ltd.

Hamilton, Bermuda: 28 march 2000 - ImuMed International Ltd., which is quoted on the Bermuda Stock Exchange (BSX symbol "IMED") announces today that it has signed a letter of intent to acquire 100% of the capital stock of Symbolistics, Ltd. of England. Symbolistics is involved in the manufacture and distribution of "near patient" diagnostic devices. Symbolistics holds or has rights to acquire the patents and technology for the manufacture of Symbol Agglutination Readers ("SAR") used in blood grouping.

The acquisition of Symbolistics is subject to ImuMed's raising $2,000,000 of working capital financing for the Symbolistics operations through an offering of ImuMed's ordinary shares, acquisition of the SAR patents and technology and completion of due diligence. This financing and the acquisition of Symbolistics and the SAR patents and technology are expected to close no later than June 30, 2000. Upon the closing, Symbolistics Limited will be a wholly owned subsidiary of ImuMed.

"The acquisition of Symbolistics will allow ImuMed to expand its serological products with new diagnostic technology as part of our plan to expand through organic growth and strategic acquisitions," said Eric F. Kohn, TD, Chairman and Chief Executive Officer of ImuMed.

Allan Syms, Non-Executive Chairman of Symbolistics stated "We believe our near patient diagnostic technology will be a significant addition to ImuMed's biotechnology capabilities."

ImuMed, a Bermuda holding corporation, is the parent corporation of ImuMed Deutschland GmbH, a German biotech and pharmaceutical manufacturing group specializing in blood typing products and related serological products. The German subsidiary group had audited Revenues in 1998 of circa US$2,167,200, an EBITDA of US$448,218, Earnings before tax of $157,105 and for the six months ending June 30th,1999 unaudited Revenues of $ 826,885, an EBITDA of $ 57,641 and Earnings before tax of $66,199.

ImuMed Deutschland GmbH consists of two operating subsidiaries Antitoxin GmbH and IFI GmbH and Co. KG based in Meckesheim, Germany near Heidelberg.

Statements made in this press release that are not historical or current facts are "forward-looking statements" made pursuant to the safe harbor provisions of federal securities laws. Forward-looking statements represent management's best judgment as to what may occur in the future, but are subject to certain risks and uncertainties that could cause actual results and events to differ materially from those presently anticipated or projected. ImuMed undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.